Back to Results
First PageMeta Content
Organofluorides / Sulfonamides / Vemurafenib / BRAF / Protein kinase inhibitor / Daiichi Sankyo / Cancer / Genentech / Metastasis / Medicine / Melanoma / Organochlorides


PRIOR AUTHORIZATION POLICY POLICY: Zelboraf® (vemurafenib tablet Genentech/Daiichi Sankyo)
Add to Reading List

Document Date: 2014-01-06 13:47:23

Open Document

File Size: 83,82 KB

Share Result on Facebook

City

South San Francisco / /

Company

Sankyo / National Comprehensive Cancer Network Inc. / Genentech USA Inc. / Daiichi Sankyo / /

Country

United States / /

Event

FDA Phase / /

Facility

National Library of Medicine / /

IndustryTerm

treatment of patients with unresectable or metastatic melanoma / in vitro diagnostic device / real-time polymerase chain reaction / /

MedicalCondition

BRAFmutated melanoma / melanoma / tumors / disease / cutaneous melanomas / advanced melanoma / wild-type BRAF melanoma / metastatic melanoma / /

Organization

Food and Drug Administration / /

/

Product

Genentech/Daiichi Sankyo / Zelboraf / GDC-0973 / V600E / /

URL

http /

SocialTag